COVID-19 clinical trials

Explore recruiting covid-19 clinical trials.

Recruiting covid-19 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

COVID-19 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19

Greece, Spain, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.

Spain, Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5091017 - AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS

Finland, Germany, Belgium, Bulgaria, Slovakia, Denmark +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)

Italy, Netherlands, France, Belgium, Estonia, Portugal +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19

Poland, Spain, Italy, Hungary, Bulgaria

Phase II and Phase III (Integrated) EU CTIS Study details

COVID-19 trials by city

COVID-19 in Toronto COVID-19 in Vancouver COVID-19 in Montreal COVID-19 in Calgary COVID-19 in Edmonton COVID-19 in Ottawa COVID-19 in Winnipeg COVID-19 in Quebec City COVID-19 in Hamilton COVID-19 in Kitchener COVID-19 in London COVID-19 in Halifax COVID-19 in New York COVID-19 in Los Angeles COVID-19 in Chicago COVID-19 in Houston

Other conditions

Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B Hepatitis C Influenza RSV Sickle cell disease Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Hearing loss Chronic fatigue syndrome